Reply to the letter to the Editor “Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts”

被引：0
|
作者：
Nicolas Simon
Jean Claude Alvarez
机构：
[1] Aix-Marseille University,APHM, INSERM, IRD, SESSTIM, Hop Sainte Marguerite, Service de Pharmacologie Clinique, CAP
[2] Hôpitaux Universitaires Paris-Ile de France-Ouest,TV
[3] APHP,Département de Pharmacologie
[4] Hôpital Raymond Poincaré,Toxicologie
[5] FHU Sepsis,undefined
[6] MasSpecLab,undefined
[7] Plateforme de spectrométrie de masse,undefined
[8] Inserm U-1173,undefined
[9] Université Paris Saclay (Versailles Saint Quentin-en-Yvelines),undefined
来源：
European Journal of Clinical Pharmacology | 2021年 / 77卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：793 / 794
页数：1
相关论文
共 50 条
  • [21] Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir
    Mas Serrano, Miguel
    Ricardo Perez-Sanchez, Javier
    Portela Sanchez, Sofia
    De la Casa-Fages, Beatriz
    Mato Jimeno, Victor
    Perez Tamayo, Isabel
    Grandas, Francisco
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 415
  • [22] Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19
    Vecchio, Gisela
    Zapico, Valeria
    Catanzariti, Alejandro
    Carboni Bisso, Indalecio
    Las Heras, Marcos
    MEDICINA-BUENOS AIRES, 2020, 80 (05) : 439 - 441
  • [23] Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
    Baldelli, Sara
    Corbellino, Mario
    Clementi, Emilio
    Cattaneo, Dario
    Gervasoni, Cristina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (09) : 2704 - 2706
  • [24] Reply to the letter to the editor "Azithromycin, treatment in COVID-19"
    Manafi, Navid
    Ghiasvand, Fereshteh
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (03)
  • [25] Reply to the letter "Evidence of effectiveness in the pharmacological management of patients with COVID-19"
    Novella Arribas, B.
    Rodriguez Salvanes, F.
    MEDICINA DE FAMILIA-SEMERGEN, 2021, 47 (04): : 281 - 281
  • [26] Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
    Stader, Felix
    Khoo, Saye
    Stoeckle, Marcel
    Back, David
    Hirsch, Hans H.
    Battegay, Manuel
    Marzolini, Catia
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (10) : 3084 - 3086
  • [27] Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)
    Schoergenhofer, Christian
    Jilma, Bernd
    Stimpfl, Thomas
    Karolyi, Mario
    Zoufaly, Alexander
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (08) : 670 - +
  • [28] Reply to Letter to Editor “Consequences of a COVID-19 Pandemic on Ophthalmologists”
    Sanjay Srinivasan
    Indian Journal of Surgery, 2021, 83 : 383 - 383
  • [29] Reply to Letter to Editor "Consequences of a COVID-19 Pandemic on Ophthalmologists"
    Srinivasan, Sanjay
    INDIAN JOURNAL OF SURGERY, 2021, 83 (01) : 383 - 383
  • [30] Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
    Zanon, D.
    Musazzi, U. M.
    Manca, A.
    Nicolo, A. De
    D'Avolio, A.
    Cilurzo, F.
    Maximova, N.
    Tomasello, C.
    Clementi, E.
    Minghetti, P.
    DATA IN BRIEF, 2020, 33
12345